2020 Revenues ($USD) : $19,410,703,364
2020 Revenues (foreign currencies) : DKK 126946000000
2020 R&D spend : $2,368,105,810
2020 Number of Employees : 45,323
Fiscal Year End : 12/31/2020
Key People : Lars Fruergaard Jørgensen, president and CEO; Monique Carter, EVP and head of people & organization; Maziar Mike Doustdar, EVP and head of international operations; Ludovic Helfgott, EVP and head of biopharm; Karsten Munk Knudsen, EVP and CFO; Doug Langa, EVP and head of North American operations, Martin Holst Lange, EVP, head of development; Marcus Schindler, EVP for research & early development and CSO; Camilla Sylvest, EVP and head of commercial strategy & corporate affairs; Henrik Wulff, EVP and head of product supply, quality & IT

The Bagsværd, Denmark–headquartered Novo Nordisk has production facilities throughout the world. Traditionally focused on diabetes, Novo Nordisk continues to sharpen its R&D focus on other chronic diseases, including obesity and Alzheimer's disease. The company continues to invest in diabetes therapies working on novel insulins and various uses for semaglutide, which works like human glucagon-like peptide-1 to boost insulin secretion. FDA has approved oral and subcutaneous versions to treat type 2 diabetes, and semaglutide also has shown promise for people who are overweight or obese. Novo Nordisk is somewhat unique among pharmaceutical companies in the degree that it seeks to minimize its environmental impact. The company reduced its carbon emissions from operations and transportations by 44% in 2020 while increasing its renewable energy at production sites by 24%. Novo Nordisk ultimately strives to have zero environmental impact. —BB